FDA's recent update on compounded versions As of early 2025 , the FDA announced that the shortages of both Semaglutide and Tirzepatide have been resolved
This study highlights an important point that weight loss is not the only factor in cancer risk reduction in the setting of GLP-1 therapy
Your provider will assist you in selecting the best option depending on your health status, insurance coverage, and lifestyle preferences
Other meta-analyses, however, despite showing that patients with BD present lower peripheral levels of tryptophan, Kyn or KYNA, did not find any significant differences between manic and depressed phases [230]
The Semaglutide Patent Landscape in 2026: A Country-by-Country Picture Semaglutide is protected not by one patent but by a patent thicket a layered portfolio of patents covering the molecule itself, formulation, delivery device, and dosing method